Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19

Persistence of Anti-S Titre among Healthcare Workers Vaccinated with BNT162b2 mRNA COVID-19

The COVID-19 pandemic has led to health, social and economic consequences for public health systems. As a result, the development of safe and effective vaccines, in order to contain the infection quickly became a priority. The first vaccine approved by the Italian Agency for Drugs Authorization (AIF...

Full description

Bibliographic Details
Main Authors:	Luca Coppeta, Giuseppina Somma, Cristiana Ferrari, Andrea Mazza, Stefano Rizza, Marco Trabucco Aurilio, Stefano Perrone, Andrea Magrini, Antonio Pietroiusti
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Series:	Vaccines
Subjects:	SARS-CoV-2 healthcare workers COVID-19 vaccine mRNA vaccine anti-S-RBD antibodies
Online Access:	https://www.mdpi.com/2076-393X/9/9/947

Similar Items

First Dose of the BNT162b2 mRNA COVID-19 Vaccine Reduces Symptom Duration and Viral Clearance in Healthcare Workers
by: Luca Coppeta, et al.
Published: (2021-06-01)

Comparative Immunogenicity of BNT162b2 mRNA Vaccine with Natural SARS-CoV-2 Infection
by: Mina Psichogiou, et al.
Published: (2021-09-01)

Induction of immune response after SARS-CoV-2 mRNA BNT162b2 vaccination in healthcare workers
by: Salvatore Zaffina, et al.
Published: (2021-06-01)

Delayed large pruritic eruption to the BNT162b2 mRNA vaccine
by: Takeshi Terashima
Published: (2021-01-01)

Delivery of mRNA Vaccine against SARS-CoV-2 Using a Polyglucin:Spermidine Conjugate
by: Larisa I. Karpenko, et al.
Published: (2021-01-01)

Antibody Response to the BNT162b2 mRNA COVID-19 Vaccine in Subjects with Prior SARS-CoV-2 Infection
by: Federico Gobbi, et al.
Published: (2021-03-01)

Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors
by: Massimo Cugno, et al.
Published: (2021-09-01)

Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
by: Tatjana Schwarz, et al.
Published: (2021-08-01)

Age- and Sex-Graded Data Evaluation of Vaccination Reactions after Initial Injection of the BNT162b2 mRNA Vaccine in a Local Vaccination Center in Germany
by: Manuela A. Hoffmann, et al.
Published: (2021-08-01)

The initial impact of a national BNT162b2 mRNA COVID-19 vaccine rollout
by: Ahmed Zaqout, et al.
Published: (2021-07-01)

Lower response to BNT162b2 vaccine in patients with myelofibrosis compared to polycythemia vera and essential thrombocythemia
by: Fulvia Pimpinelli, et al.
Published: (2021-07-01)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
by: Emanuel Zitt, et al.
Published: (2021-06-01)

Evaluation of Immunity for Mumps among Vaccinated Medical Students
by: Cristiana Ferrari, et al.
Published: (2021-06-01)

Humoral and Cellular Response Following Vaccination With the BNT162b2 mRNA COVID-19 Vaccine in Patients Affected by Primary Immunodeficiencies
by: Donato Amodio, et al.
Published: (2021-10-01)

A systematic review of effectiveness of BNT162b2 mRNA and ChAdOx1 adenoviral vector COVID-19 vaccines in the general population
by: Chinonyerem O. Iheanacho, et al.
Published: (2021-08-01)

Comparative effectiveness of BNT162B2 and mRNA-1273 vaccines in U.S. Veterans
by: Casas, J.P, et al.
Published: (2022)

BNT162b2 COVID-19 Vaccine Hesitancy among Parents of 4023 Young Adolescents (12–15 Years) in Qatar
by: Sarah Musa, et al.
Published: (2021-09-01)

SARS-CoV-2 anti-spike antibody titres after vaccination with BNT162b2 in naïve and previously infected individuals
by: Andrea Lombardi, et al.
Published: (2021-08-01)

Fifth-week immunogenicity and safety of anti-SARS-CoV-2 BNT162b2 vaccine in patients with multiple myeloma and myeloproliferative malignancies on active treatment: preliminary data from a single institution
by: Fulvia Pimpinelli, et al.
Published: (2021-05-01)

Heterologous ChAdOx1 nCoV-19/BNT162b2 Prime-Boost Vaccination Induces Strong Humoral Responses among Health Care Workers
by: Louise Benning, et al.
Published: (2021-08-01)

Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients
by: Ioannis P. Trougakos, et al.
Published: (2021-08-01)

Early Serological Response to BNT162b2 mRNA Vaccine in Healthcare Workers
by: Giovanna Cocomazzi, et al.
Published: (2021-08-01)

Differential immunogenicity of BNT162b2 or ChAdOx1 vaccines after extended-interval homologous dual vaccination in older people
by: Helen Parry, et al.
Published: (2021-08-01)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)

Early effectiveness of BNT162b2 Covid-19 vaccine in preventing SARS-CoV-2 infection in healthcare personnel in six Israeli hospitals (CoVEHPI)
by: Akriv, A., et al.
Published: (2022)

MERS Vaccine Candidate Offers Promise, but Questions Remain
by: Vineet D. Menachery
Published: (2015-10-01)

Immune response and reactogenicity after immunization with two-doses of an experimental COVID-19 vaccine (CVnCOV) followed by a third-fourth shot with a standard mRNA vaccine (BNT162b2): RescueVacs multicenter cohort study
by: Alcamí, J., et al.
Published: (2022)

Evaluation of Anti-SARS-Cov-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine
by: Bruna Lo Sasso, et al.
Published: (2021-06-01)

Side effects of BNT162b2 mRNA COVID-19 vaccine: A randomized, cross-sectional study with detailed self-reported symptoms from healthcare workers
by: Renuka A.K. Kadali, et al.
Published: (2021-05-01)

Coordinate Induction of Humoral and Spike Specific T-Cell Response in a Cohort of Italian Health Care Workers Receiving BNT162b2 mRNA Vaccine
by: Chiara Agrati, et al.
Published: (2021-06-01)

Intranasal Administration of RBD Nanoparticles Confers Induction of Mucosal and Systemic Immunity against SARS-CoV-2
by: Tuksin Jearanaiwitayakul, et al.
Published: (2021-07-01)

BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
by: Ahmed N. Alghamdi, et al.
Published: (2021-10-01)

Robust Antibody Responses to the BNT162b2 mRNA Vaccine Occur Within a Week After the First Dose in Previously Infected Individuals and After the Second Dose in Uninfected Individuals
by: Yosuke Hirotsu, et al.
Published: (2021-08-01)

Humoral Response to SARS-CoV-2-Vaccination with BNT162b2 (Pfizer-BioNTech) in Patients on Hemodialysis
by: Michael Jahn, et al.
Published: (2021-04-01)

Tolerability of Coronavirus Disease 2019 Vaccines, BNT162b2 and mRNA-1273, in Patients With Thymic Epithelial Tumors
by: Madison Ballman, BA, et al.
Published: (2021-10-01)

Systemic IL-15, IFN-γ, and IP-10/CXCL10 signature associated with effective immune response to SARS-CoV-2 in BNT162b2 mRNA vaccine recipients
by: Cristina Bergamaschi, et al.
Published: (2021-08-01)

Evidence of SARS-CoV-2-Specific Memory B Cells Six Months After Vaccination With the BNT162b2 mRNA Vaccine
by: Annalisa Ciabattini, et al.
Published: (2021-09-01)

SARS-CoV-2 Gamma and Delta Variants of Concern Might Undermine Neutralizing Activity Generated in Response to BNT162b2 mRNA Vaccination
by: Cipolletta, D., et al.
Published: (2022)

Effectiveness of CoronaVac and BNT162b2 COVID-19 mass vaccination in Colombia: A population-based cohort study
by: Alvis-Guzmán, N., et al.
Published: (2022)

Immune thrombocytopenia associated with Pfizer-BioNTech’s BNT162b2 mRNA COVID-19 vaccine
by: Hiroaki Akiyama, et al.
Published: (2021-01-01)